We are live on
!
Find out more
Deerfield Management Portfolio holdings
AUM
$9.59B
Turnover
24.47%
1-Year Est. Return
113.36%
This Fund
S&P 500
This Quarter
Est. Return
+6.55%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$8.48B
AUM Growth
+$646M
(+8.3%)
Cap. Flow
-$743M
Cap. Flow
% of AUM
-8.77%
Top 10 Holdings %
Top 10 Hldgs %
50.85%
Holding
160
New
9
Increased
14
Reduced
10
Closed
78
Avg Time Held Equity + Options
2
years
Top 10 Avg Time Held Equity + Options
1.1
years
Top 20 Avg Time Held Equity + Options
1.5
years
Avg Time Held Equity only
2
years
Top 10 Avg Time Held Equity only
1.1
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inspire Medical Systems
INSP
|
+$83.8M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$82.1M |
| 3 |
Pfizer
PFE
|
+$80.9M |
| 4 |
Genmab
GMAB
|
+$73.8M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$59.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$76.2M |
| 2 |
Revolution Medicines
RVMD
|
+$60.3M |
| 3 |
Phreesia
PHR
|
+$33.8M |
| 4 |
Ventas
VTR
|
+$27.4M |
| 5 |
Spyre Therapeutics
SYRE
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.65% |
| 2 | Miscellaneous | 15.35% |
| 3 | Consumer Discretionary | 0% |
| 4 | Consumer Staples | 0% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Dianthus Therapeutics
DNTH
$4.03B
| $85.6M | 1.01% |
+1,019,813
| New | +$59.1M |
2026 Q1
0 quarters
|
|
|
27
Pfizer
PFE
$169B
| $85.4M | 1.01% |
+3,040,000
| New | +$80.9M |
2026 Q1
0 quarters
|
|
|
28
Neurocrine Biosciences
NBIX
$13.8B
| $80.4M | 0.95% |
610,000
-574,345
| -48% | -$76.2M |
2021 Q1
20 quarters
|
|
29
DELISTED
Day One Biopharmaceuticals
DAWN
| $79.8M | 0.94% |
3,723,131
| – | – |
2023 Q2
11 quarters
|
|
30
Savara
SVRA
$914M
| $74.1M | 0.87% |
13,569,000
| – | – |
2024 Q3
6 quarters
|
|
31
DELISTED
Enhabit
EHAB
| $66.9M | 0.79% |
4,747,746
| – | – |
2022 Q3
14 quarters
|
|
|
32
Genmab
GMAB
$22.8B
| $66.1M | 0.78% |
+2,462,000
| New | +$73.8M |
2026 Q1
0 quarters
|
|
33
Bio-Rad Laboratories Class A
BIO
$9.46B
| $63M | 0.74% |
226,070
| – | – |
2023 Q3
10 quarters
|
|
34
Lantheus
LNTH
$6.51B
| $62.8M | 0.74% |
827,999
| – | – |
2025 Q4
1 quarter
|
|
35
ARS Pharmaceuticals
SPRY
$400M
| $60.3M | 0.71% |
7,503,812
| – | – |
2022 Q4
13 quarters
|
|
36
Stoke Therapeutics
STOK
$1.56B
| $59.4M | 0.7% |
1,823,500
| – | – |
2025 Q4
1 quarter
|
|
37
Envista
NVST
$3.68B
| $56.1M | 0.66% |
2,210,100
-70,398
| -3% | -$1.83M |
2024 Q3
6 quarters
|
|
38
IDEAYA Biosciences
IDYA
$3.17B
| $51M | 0.6% |
1,530,008
-623,035
| -29% | -$20.9M |
2022 Q3
14 quarters
|
|
39
Belite Bio
BLTE
$5.75B
| $48.5M | 0.57% |
304,013
+70,200
| +30% | +$11.8M |
2025 Q4
1 quarter
|
|
40
BioMarin Pharmaceuticals
BMRN
$10.6B
| $48.1M | 0.57% |
+851,556
| New | +$49.7M |
2026 Q1
0 quarters
|
|
41
Kymera Therapeutics
KYMR
$8.71B
| $46.7M | 0.55% |
561,170
| – | – |
2024 Q4
5 quarters
|
|
42
Certara
CERT
$1.43B
| $44.5M | 0.53% |
7,808,605
| – | – |
2025 Q1
4 quarters
|
|
43
BridgeBio Oncology
BBOT
$226M
| $43.7M | 0.52% |
4,885,446
| – | – |
2025 Q3
2 quarters
|
|
44
Disc Medicine
IRON
$2.18B
| $42M | 0.5% |
657,000
+145,837
| +29% | +$10.1M |
2023 Q2
11 quarters
|
|
45
Sionna Therapeutics
SION
$176M
| $38.9M | 0.46% |
970,590
| – | – |
2025 Q1
4 quarters
|
|
46
CareDx
CDNA
$3.31B
| $38M | 0.45% |
2,191,000
| – | – |
2025 Q3
2 quarters
|
|
47
Structure Therapeutics
GPCR
$1.5B
| $37M | 0.44% |
767,993
| – | – |
2023 Q1
12 quarters
|
|
48
Veracyte
VCYT
$3.47B
| $23.4M | 0.28% |
726,000
| – | – |
2025 Q2
3 quarters
|
|
49
Alnylam Pharmaceuticals
ALNY
$31B
| $22.5M | 0.27% |
67,935
| – | – |
2024 Q2
7 quarters
|
|
50
Embecta
EMBC
$355M
| $22.4M | 0.26% |
2,534,961
-217,070
| -8% | -$2.26M |
2023 Q4
9 quarters
|
|
Similar funds
GGHC
SC
Deerfield Management's Q1 2026 Portfolio in Review
As of Q1 2026, Deerfield Management held 160 positions worth $8.48B, up 8.3% from $7.83B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Deerfield Management withdrew a net $743M in Q1 2026, closing 78 positions and reducing 10 holdings. Its most notable exit was Phreesia, an estimated $33.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
Against the trend, Deerfield Management opened a new position in Syndax Pharmaceuticals worth $88.3M.
- Deerfield Management's largest Q1 2026 buy was Syndax Pharmaceuticals: 3,779,900 shares worth $88.3M.
- Deerfield Management added most to Inspire Medical Systems in Q1 2026, an estimated $83.8M increase.
- Deerfield Management's biggest Q1 2026 reduction was Neurocrine Biosciences, cutting an estimated $76.2M.
- Deerfield Management fully exited Phreesia in Q1 2026, selling an estimated $33.8M.
- Deerfield Management's ten largest holdings make up 51% of its $8.48B portfolio in Q1 2026.
- Deerfield Management opened 9 new positions and closed 78 in Q1 2026.
- Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $8.48B.
Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.